Logo image of DARE

DARE BIOSCIENCE INC (DARE) Stock Fundamental Analysis

NASDAQ:DARE - Nasdaq - US23666P2002 - Common Stock - Currency: USD

2.91  -0.01 (-0.34%)

Fundamental Rating

3

DARE gets a fundamental rating of 3 out of 10. The analysis compared the fundamentals against 198 industry peers in the Pharmaceuticals industry. While DARE seems to be doing ok healthwise, there are quite some concerns on its profitability. DARE is valied quite expensively at the moment, while it does show a decent growth rate.


Dividend Valuation Growth Profitability Health

Quickly go to:

2

1. Profitability

1.1 Basic Checks

In the past year DARE has reported negative net income.
DARE had a positive operating cash flow in the past year.
DARE had negative earnings in each of the past 5 years.
In the past 5 years DARE reported 4 times negative operating cash flow.
DARE Yearly Net Income VS EBIT VS OCF VS FCFDARE Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -10M -20M -30M

1.2 Ratios

DARE has a better Return On Assets (-18.34%) than 62.12% of its industry peers.
Industry RankSector Rank
ROA -18.34%
ROE N/A
ROIC N/A
ROA(3y)-76.89%
ROA(5y)-132.61%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
DARE Yearly ROA, ROE, ROICDARE Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 2K -2K -4K -6K -8K

1.3 Margins

The Gross Margin of DARE (100.00%) is better than 100.00% of its industry peers.
DARE does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 100%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
DARE Yearly Profit, Operating, Gross MarginsDARE Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -50K -100K -150K -200K

More info and screens

4

2. Health

2.1 Basic Checks

DARE does not have a ROIC to compare to the WACC, probably because it is not profitable.
DARE has more shares outstanding than it did 1 year ago.
The number of shares outstanding for DARE has been reduced compared to 5 years ago.
There is no outstanding debt for DARE. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
DARE Yearly Shares OutstandingDARE Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M
DARE Yearly Total Debt VS Total AssetsDARE Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M

2.2 Solvency

DARE has an Altman-Z score of -14.22. This is a bad value and indicates that DARE is not financially healthy and even has some risk of bankruptcy.
Looking at the Altman-Z score, with a value of -14.22, DARE is doing worse than 77.27% of the companies in the same industry.
There is no outstanding debt for DARE. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF 0
Altman-Z -14.22
ROIC/WACCN/A
WACC9.79%
DARE Yearly LT Debt VS Equity VS FCFDARE Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20M -20M 40M

2.3 Liquidity

DARE has a Current Ratio of 0.85. This is a bad value and indicates that DARE is not financially healthy enough and could expect problems in meeting its short term obligations.
With a Current ratio value of 0.85, DARE is not doing good in the industry: 87.37% of the companies in the same industry are doing better.
DARE has a Quick Ratio of 0.85. This is a bad value and indicates that DARE is not financially healthy enough and could expect problems in meeting its short term obligations.
The Quick ratio of DARE (0.85) is worse than 82.32% of its industry peers.
Industry RankSector Rank
Current Ratio 0.85
Quick Ratio 0.85
DARE Yearly Current Assets VS Current LiabilitesDARE Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M

More info and screens

4

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 87.25% over the past year.
DARE shows a very negative growth in Revenue. In the last year, the Revenue has decreased by -97.39%.
EPS 1Y (TTM)87.25%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%9.72%
Revenue 1Y (TTM)-97.39%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%-103.54%

3.2 Future

DARE is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 93.90% yearly.
DARE is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 219.09% yearly.
EPS Next Y-295.58%
EPS Next 2Y-52.46%
EPS Next 3Y43.44%
EPS Next 5Y93.9%
Revenue Next Year-20.21%
Revenue Next 2Y290.24%
Revenue Next 3Y270.28%
Revenue Next 5Y219.09%

3.3 Evolution

DARE Yearly Revenue VS EstimatesDARE Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2016 2018 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 200M 400M 600M
DARE Yearly EPS VS EstimatesDARE Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2015 2016 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 -100 -200 -300 -400 -500

More info and screens

2

4. Valuation

4.1 Price/Earnings Ratio

DARE reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for DARE. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
DARE Price Earnings VS Forward Price EarningsDARE Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 5 -5 10 15 20

4.2 Price Multiples

DARE's Price/Free Cash Flow ratio is rather cheap when compared to the industry. DARE is cheaper than 96.46% of the companies in the same industry.
Industry RankSector Rank
P/FCF 5.34
EV/EBITDA N/A
DARE Per share dataDARE EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.5 -0.5 -1 -1.5 -2

4.3 Compensation for Growth

A more expensive valuation may be justified as DARE's earnings are expected to grow with 43.44% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-52.46%
EPS Next 3Y43.44%

More info and screens

0

5. Dividend

5.1 Amount

DARE does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

DARE BIOSCIENCE INC

NASDAQ:DARE (5/9/2025, 8:00:01 PM)

2.91

-0.01 (-0.34%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)05-05 2025-05-05
Earnings (Next)08-11 2025-08-11
Inst Owners8.99%
Inst Owner Change6.96%
Ins Owners1.17%
Ins Owner Change0%
Market Cap25.75M
Analysts80
Price Target13.6 (367.35%)
Short Float %0.54%
Short Ratio2.16
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)3.49%
Min EPS beat(2)-19.49%
Max EPS beat(2)26.47%
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)0
Avg Revenue beat(2)-102.35%
Min Revenue beat(2)-104.71%
Max Revenue beat(2)-100%
Revenue beat(4)0
Avg Revenue beat(4)-100.26%
Min Revenue beat(4)-104.71%
Max Revenue beat(4)-96.61%
Revenue beat(8)1
Avg Revenue beat(8)-59.67%
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)-37.5%
EPS NQ rev (1m)0%
EPS NQ rev (3m)23.68%
EPS NY rev (1m)-63.51%
EPS NY rev (3m)-63.51%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-50%
Revenue NY rev (1m)0%
Revenue NY rev (3m)-66.27%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 350.87
P/FCF 5.34
P/OCF 4.77
P/B N/A
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-0.52
EYN/A
EPS(NY)-2.06
Fwd EYN/A
FCF(TTM)0.54
FCFY18.72%
OCF(TTM)0.61
OCFY20.95%
SpS0.01
BVpS-0.68
TBVpS-0.68
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -18.34%
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 100%
FCFM 6568.39%
ROA(3y)-76.89%
ROA(5y)-132.61%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF 0
Debt/EBITDA N/A
Cap/Depr 1354.61%
Cap/Sales 780.65%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 0.85
Quick Ratio 0.85
Altman-Z -14.22
F-Score4
WACC9.79%
ROIC/WACCN/A
Cap/Depr(3y)1097.89%
Cap/Depr(5y)675.4%
Cap/Sales(3y)1956.65%
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)87.25%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%9.72%
EPS Next Y-295.58%
EPS Next 2Y-52.46%
EPS Next 3Y43.44%
EPS Next 5Y93.9%
Revenue 1Y (TTM)-97.39%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%-103.54%
Revenue Next Year-20.21%
Revenue Next 2Y290.24%
Revenue Next 3Y270.28%
Revenue Next 5Y219.09%
EBIT growth 1Y24.21%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y112.21%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y113.88%
OCF growth 3YN/A
OCF growth 5YN/A